Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the safety and immunogenicity of inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (Vero cells) in healthy population aged 6 years and above in a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial

Next Previous
Trial Profile

Evaluation of the safety and immunogenicity of inactivated Novel Coronavirus Pneumonia (COVID-19) vaccine (Vero cells) in healthy population aged 6 years and above in a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 24 Aug 2020 New source identified and integrated (Chinese Clinical Trial Register: ChiCTR2000031809)
  • 13 Aug 2020 Interim results (n=320; as of 16 Jun 2020) published in the JAMA: the Journal of the American Medical Association
  • 07 Jul 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top